GIMBHI’s daily mental health update — 8/19/26

🤖 JAMA Psychiatry: Does interacting with AI cause delusions? (Philip R. Corlett, JAMA Psychiatry) — 08/19/26 TL;DR: Yale’s Corlett argues sycophantic LLMs can induce delusion-like beliefs (”folie induire”), urges clinicians to ask patients about AI use, and suggests using AI as a therapeutic tool to counter such beliefs.

🧠 Kantoko raises $3.5M seed to simplify Australia’s ADHD assessment and treatment (Daniel Van Boom, Forbes Australia) — 08/13/26 TL;DR: Founded by ex-LoungeBuddy CEO Zac Altman, Kantoko raised $3.5M led by Side Stage Ventures with backing from Andrew Forrest’s Tenmile to expand its $100/month telehealth ADHD platform for underserved Australians.

📈 BrainsWay Q2 2026 revenue jumps 35% to record $17.1M, raises full-year guidance (BrainsWay Ltd., BioSpace) — 08/12/26 TL;DR: BrainsWay shipped a record 125 Deep TMS systems (+42% YoY), doubled adjusted EBITDA to $3.5M, expanded SWIFT reimbursement, and added minority investments in Hopemark Health and Radial Health.

🎯 Suicide risk models are ready — our health systems are not (Yunyu Xiao et al., JAMA Psychiatry) — 08/19/26 TL;DR: EHR-based suicide risk prediction models work but lack shared infrastructure for deployment; authors call for federated benchmarking, site-specific model selection, and evaluation of multimodal social determinants data.